Clinical studies of reversal of drug resistance based on glutathione.

作者: Paula Calvert , Kang-Shen Yao , Thomas C Hamilton , Peter J O’Dwyer

DOI: 10.1016/S0009-2797(98)00008-8

关键词: Buthionine sulfoximineGlutathioneCancer cellHomeostasisCellular homeostasisPharmacologyMechanism (biology)BiologyCisplatinDrug resistance

摘要: The greater affinity of electrophiles for thiol groups than hydroxyl or amine provides a teleological basis the evolution this mechanism to assist in maintenance cellular homeostasis. As most abundant non-protein thiol, glutathione (GSH) is pivotal protection cells from created during normal respiration and after exposure environmental mutagens. Mutagens many anti-cancer drugs, e.g. cisplatin alkylating agents, have same target, i.e. DNA. This suggested that one by which cancer might circumvent action chemotherapeutic agents would be increasing their GSH and/or enhanced conjugation these drugs tripeptide. chapter describes preclinical data support resistance platinum agents. was rationale development pharmacologic strategies lower inactivate gluathione-S-transferases make more effective. positive outcome studies enhance activity melaphalan are described as status on going clinical trials built around data.

参考文章(32)
Peter J. O'Dwyer, Andrew K. Godwin, Robert F. Ozols, Kang-Shen Yao, Thomas C. Hamilton, Steven W. Johnson, Evidence for Altered Regulation of γ-Glutamylcysteine Synthetase Gene Expression among Cisplatin-sensitive and Cisplatin-resistant Human Ovarian Cancer Cell Lines Cancer Research. ,vol. 55, pp. 4367- 4374 ,(1995)
Wilma M. McKoy, Karen R. Grotzinger, Timothy J. Kinsella, Karen G. Louie, Robert F. Ozols, Margaret A. Winker, Brent C. Behrens, Thomas C. Hamilton, Radiation Survival Parameters of Antineoplastic Drug-sensitive and -resistant Human Ovarian Cancer Cell Lines and Their Modification by Buthionine Sulfoximine Cancer Research. ,vol. 45, pp. 2110- 2115 ,(1985)
O'Dwyer Pj, Ford P, Yao Ks, Godwin Ak, Clayton M, Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells Cancer Research. ,vol. 54, pp. 3082- 3087 ,(1994)
Yoshihiro Matsumoto, Christina Khater, Ann Krueger, Thomas C. Hamilton, Steven W. Johnson, Peter J. O'Dwyer, Kang-Shen Yao, The Chemopreventive Agent Oltipraz Stimulates Repair of Damaged DNA Cancer Research. ,vol. 57, pp. 1050- 1053 ,(1997)
Howard H. Bailey, R. Timothy Mulcahy, Maureen Ripple, Jerry J. Gipp, George Wilding, Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Research. ,vol. 52, pp. 5115- 5118 ,(1992)
H H Bailey, R T Mulcahy, K D Tutsch, R Z Arzoomanian, D Alberti, M B Tombes, G Wilding, M Pomplun, D R Spriggs, Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Journal of Clinical Oncology. ,vol. 12, pp. 194- 205 ,(1994) , 10.1200/JCO.1994.12.1.194
Peter J. O'Dwyer, Andrew K. Godwin, Robert F. Ozols, Kang-shen Yao, Thomas C. Hamilton, Variable Baseline γ-Glutamylcysteine Synthetase Messenger RNA Expression in Peripheral Mononuclear Cells of Cancer Patients, and Its Induction by Buthionine Sulfoximine Treatment Cancer Research. ,vol. 53, pp. 3662- 3666 ,(1993)
Carl F. Nathan, Bradley A. Arrick, Glutathione Metabolism as a Determinant of Therapeutic Efficacy: A Review Cancer Research. ,vol. 44, pp. 4224- 4232 ,(1984)
P J O'Dwyer, T C Hamilton, F P LaCreta, J M Gallo, D Kilpatrick, T Halbherr, J Brennan, M A Bookman, J Hoffman, R C Young, R L Comis, R F Ozols, Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Journal of Clinical Oncology. ,vol. 14, pp. 249- 256 ,(1996) , 10.1200/JCO.1996.14.1.249